{"id":"caiv-t-and-tiv","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal congestion"},{"rate":null,"effect":"Runny nose"},{"rate":null,"effect":"Sore throat"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CAIV-T (Cold-Adapted Influenza Vaccine - Trivalent) uses temperature-sensitive, live attenuated virus that replicates in the cooler upper respiratory tract to stimulate mucosal and systemic immunity. TIV (Trivalent Inactivated Vaccine) contains inactivated influenza virus particles administered intramuscularly to generate humoral immune responses. The phase 3 comparison likely evaluates relative efficacy, safety, and immunogenicity between these two vaccine modalities.","oneSentence":"CAIV-T is a live attenuated influenza vaccine administered intranasally, while TIV is a trivalent inactivated influenza vaccine, both designed to induce immune responses against seasonal influenza strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:25.070Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in pediatric and/or adult populations"}]},"trialDetails":[{"nctId":"NCT00192387","phase":"PHASE2","title":"Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-09","conditions":"Influenza","enrollment":60},{"nctId":"NCT00192231","phase":"PHASE3","title":"Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-04","conditions":"Influenza","enrollment":120},{"nctId":"NCT00128167","phase":"PHASE3","title":"Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2004-10","conditions":"Influenza","enrollment":8500},{"nctId":"NCT00192153","phase":"PHASE2","title":"Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-07","conditions":"Influenza","enrollment":240},{"nctId":"NCT00192348","phase":"PHASE1","title":"A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-05","conditions":"Healthy","enrollment":120},{"nctId":"NCT00344305","phase":"PHASE2","title":"A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2006-05-01","conditions":"Healthy","enrollment":200},{"nctId":"NCT00192413","phase":"PHASE3","title":"Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-03","conditions":"Influenza","enrollment":3009},{"nctId":"NCT00192270","phase":"PHASE2","title":"Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2000-10","conditions":"Healthy","enrollment":498},{"nctId":"NCT00192179","phase":"PHASE2","title":"A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2003-06","conditions":"Influenza","enrollment":240},{"nctId":"NCT00192309","phase":"PHASE2","title":"Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-09","conditions":"Influenza","enrollment":31},{"nctId":"NCT00224783","phase":"PHASE1","title":"Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-08","conditions":"Healthy Japanese Male Adults","enrollment":45},{"nctId":"NCT00001127","phase":"PHASE3","title":"Study of a Flu Vaccine in Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Influenza","enrollment":15000},{"nctId":"NCT00192283","phase":"PHASE3","title":"Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2000-09","conditions":"Influenza","enrollment":2903},{"nctId":"NCT00192166","phase":"PHASE2","title":"Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-10","conditions":"Influenza","enrollment":1200},{"nctId":"NCT00192335","phase":"PHASE3","title":"Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2004-07","conditions":"Healthy","enrollment":890},{"nctId":"NCT00192361","phase":"PHASE3","title":"Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"1999-11","conditions":"Influenza","enrollment":200},{"nctId":"NCT00192205","phase":"PHASE3","title":"Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-10","conditions":"Respiratory Tract Infections","enrollment":2200},{"nctId":"NCT00192400","phase":"PHASE3","title":"Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-03","conditions":"Healthy","enrollment":2160},{"nctId":"NCT00217230","phase":"PHASE3","title":"Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-04","conditions":"Influenza","enrollment":3000},{"nctId":"NCT00192257","phase":"PHASE3","title":"Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-10","conditions":"Asthma","enrollment":2229},{"nctId":"NCT00192244","phase":"PHASE3","title":"Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2000-09","conditions":"Healthy","enrollment":3000},{"nctId":"NCT00192426","phase":"PHASE3","title":"Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-09","conditions":"Influenza","enrollment":2400},{"nctId":"NCT00192374","phase":"PHASE3","title":"Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-02","conditions":"Healthy","enrollment":1920}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CAIV-T and TIV","genericName":"CAIV-T and TIV","companyName":"MedImmune LLC","companyId":"medimmune-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"CAIV-T is a live attenuated influenza vaccine administered intranasally, while TIV is a trivalent inactivated influenza vaccine, both designed to induce immune responses against seasonal influenza strains. Used for Seasonal influenza prevention in pediatric and/or adult populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}